FMNL2

Across TCGA pan-cancer cohorts, FMNL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FMNL2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher FMNL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FMNL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

COAD, CCRCC, and PDAC are the cancer types where FMNL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	0.746	1.000	.014	42	view →
CCRCC	DFS	Median	II,III,IV	0.740	0.999	.001	34	view →
PDAC	OS	Tertile	All	0.258	0.503	.027	5	view →
GBM	OS	Tertile	All	0.356	0.669	.013	2	view →
LSCC	OS	Tertile	III,IV	0.983	0.590	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FMNL2–COAD (DFS)

Open the COAD breakdown →